Advertisement
UK markets close in 7 hours 1 minute

  • FTSE 100

    8,089.41
    +49.03 (+0.61%)
     

  • FTSE 250

    19,672.72
    -46.65 (-0.24%)
     

  • AIM

    754.44
    -0.25 (-0.03%)
     

  • GBP/EUR

    1.1666
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2512
    +0.0050 (+0.40%)
     

  • Bitcoin GBP

    51,151.71
    -2,087.27 (-3.92%)
     

  • CMC Crypto 200

    1,363.30
    -19.28 (-1.40%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    83.17
    +0.36 (+0.43%)
     

  • GOLD FUTURES

    2,338.70
    +0.30 (+0.01%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    18,027.80
    -60.90 (-0.34%)
     

  • CAC 40

    8,071.13
    -20.73 (-0.26%)
     
Property:

How to sell your home

Top tips from property investors

Astra looking to partner or sell infection, neuroscience drugs

Reuters

LONDON (Reuters) - AstraZeneca is looking to partner or sell its anti-infective and neuroscience drugs, since these products are no longer core areas for the British drugmaker, its chief executive said on Thursday.

Pascal Soriot told reporters in a first-quarter conference call that he was investigating all options for the businesses as the drugmaker redeploys resources to the priority areas of oncology, cardiovascular and metabolic diseases, and respiratory and inflammation.

(Reporting by Ben Hirschler; Editing by Mark Potter)